AbbVie Inc. ABBV
291.31 USD +3.07 (+1.07%)
At closeNov 6, 2026, 6:26 PM EST
291.31 0.00 0.00%
After hours · Nov 6, 6:26 PM ET
281.07 Day range 291.73
197.38 52-week range 294.89
- YTD
- +27.49%
- 1 year
- +32.99%
News
benzinga.com Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 3.3% on an annualized basis producing an average annual return of 16.33%. Currently, AbbVie has a market capitalization of…
zacks.com Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
seekingalpha.com Dividend Announcements: October 24-30, 2026 (Part 1 Of 2) I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify conviction opportunities. V, APH, and HIG stand out for robust…
reuters.com AbbVie expands Oxford R&D facility as part of £120 million-plus investment AbbVie expands Oxford R&D facility as part of £120 million-plus investment
247wallst.com AbbVie Hit a New High After Earnings. There's More Upside Left. AbbVie just logged a 33% gain for the year and raised its guidance again, but the real question is whether Skyrizi and a newly closed pipeline deal can push shares even further past a valuation that…
prnewswire.com Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026 – Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial…
defenseworld.net AbbVie Inc. $ABBV Position Lessened by BOCHK Asset Management Ltd BOCHK Asset Management Ltd cut its holdings in AbbVie Inc. (NYSE: ABBV) by 52.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange…
benzinga.com UBS Maintains Neutral on AbbVie, Raises Price Target to $295 UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $275 to $295.
marketbeat.com AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test AbbVie TodayABBVAbbVie$288.82 -6.07 (-2.06%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$190.75▼$298.74Dividend Yield2.40%P/E…
benzinga.com Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $346 Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $310 to $346.
fool.com The Best Dividend Stocks to Buy With $5,000 in November AbbVie survived its loss of Humira, and its profits are soaring. J&J's streamlining efforts are paying off.
benzinga.com AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To Reaccelerate AbbVie shares fell 2% despite Q3 revenue and EPS beats; analysts raised targets, citing immunology strength and long-term growth prospects.
zacks.com ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress AbbVie raises its 2026 revenue and earnings outlook as Skyrizi, Rinvoq and neuroscience growth fuel momentum, while oncology milestones shape prospects.
benzinga.com Growth And Cyclical Sectors Lead Monday Trading Seven sectors are higher and four are lower in Monday’s regular session, with growth and cyclical sectors splitting the top of the table. The leaders are separated rather than clustered, with no…
fool.com AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027? AbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products. Bristol Myers Squibb offers a high-margin portfolio focused on…
benzinga.com Guggenheim Maintains Buy on AbbVie, Raises Price Target to $322 Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $288 to $322.- benzinga.com Brise Pharmaceuticals Announces Its 2024 License Deal Value With AbbVie Could Reach Up To $775M For Two Of Brise's Preclinical Migraine Programs Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration…
247wallst.com 4 Elite Dividend Stocks That Pay You Passive Income Every Quarter When you're drawing income from a portfolio, the check size matters less than whether it keeps coming every year. A blue-chip payout is funded by free cash flow left over after the business reinvests…
benzinga.com Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $340 Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $300 to $340.
247wallst.com 2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever Arthritis flares, cholesterol checks and cancer treatments arrive on their own schedule, in recessions and booms alike, which is why healthcare draws attention from retirees building an income plan.…
benzinga.com These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results AbbVie Inc. (NYSE:ABBV) on Friday reported better-than-expected third-quarter 2026 results and raised its full-year outlook.- benzinga.com These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results AbbVie beats Q3 estimates, raises 2026 revenue and earnings outlook, while analysts lift price targets to as high as $338.
benzinga.com RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $330 RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $280 to $330.
benzinga.com Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $338 Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $290 to $338.- benzinga.com Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $325 Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $290 to $325.
benzinga.com AbbVie, FTAI Aviation, eBay And More: CNBC's ‘Final Trades' On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, recommended AbbVie Inc. (NYSE:ABBV).- benzinga.com AbbVie, FTAI Aviation, eBay And More: CNBC’s ‘Final Trades’ CNBC traders picked eBay, GPIQ, AbbVie and FTAI, citing earnings, guidance, income potential and buybacks; shares had mixed Friday moves.
defenseworld.net 87,345 AbbVie Inc. $ABBV Shares Purchased by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich grew its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 19.2% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The…
fool.com Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo AbbVie's ABBV-466 nearly doubled Skyrizi's Crohn's remission rate in a Phase 2 study. Analysts see it as a potentially more effective follow-up to Skyrizi.
seekingalpha.com Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November Emerson is set to extend its dividend growth streak to 70 years, with a predicted 6.3–8.1% increase driven by a business transformation. EMR's shift to higher-margin Intelligent Devices and Software…
fool.com AbbVie: 3 Key Takeaways for Long-Term Investors AbbVie raised full-year net revenue guidance to $67.8 billion. Skyrizi and Rinvoq delivered $6 billion in combined growth this year.
fool.com Is AbbVie a Buy After Its Latest Earnings Report? Adjusted EPS nearly doubled, but most of that comes from last year's big research-deal charge, and underlying growth was closer to 17%. Skyrizi and Rinvoq now account for nearly half of AbbVie's…
benzinga.com AbbVie Raises 2026 Outlook, Boosts Dividend AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.
benzinga.com Defensives Lead Sectors In Friday Trading As Growth Trails Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
benzinga.com AbbVie Q3 2026 Earnings Call Transcript AbbVie (NYSE:ABBV) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Conference call:
AbbVie Raises FY2026 Sales Guidance from $67.600B to $67.800B vs $67.585B Est AbbVie (NYSE:ABBV) raises FY2026 sales outlook from $67.600 billion to $67.800 billion vs $67.585 billion estimate.
benzinga.com Conference call:
AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.- benzinga.com AbbVie Q3 Adj. EPS $3.82 Beats $3.75 Estimate, Sales $17.404B Beat $17.314B Estimate AbbVie (NYSE:ABBV) reported quarterly earnings of $3.82 per share which beat the analyst consensus estimate of $3.75 by 1.87 percent. This is a 105.38 percent increase over earnings of $1.86 per…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will S&P 500 open higher? Polymarket odds plunge to 14% as Wall Street reacts to Alphabet's 10% drop, rising oil, and a broad tech selloff.
benzinga.com ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…
benzinga.com 8 Of 11 Sectors Rise Thursday As Defensives Lead Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…
benzinga.com Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.- benzinga.com AbbVie Announces Publication Of Results From Phase 3 TEMPLE Study In The Lancet Neurology; Study Results Showed Atogepant Outperformed Topiramate In Migraine Prevention Phase 3 TEMPLE study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) compared with topiramate for the preventive treatment of migraine in adults with a history of four or more…
- benzinga.com AbbVie Submits BLA To FDA For Etentamig, Second-Gen BCMA X CD3 Bispecific Antibody T-Cell Engager Administered Intravenously For Treatment Of Adults With Relapsed Or Refractory Multiple Myeloma – Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of…
benzinga.com Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.65%. Currently, AbbVie has a market capitalization of…- benzinga.com AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely…
- benzinga.com Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294 Goldman Sachs analyst Asad Haider maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $258 to $294.
benzinga.com What's Going On with MoonLake Immunotherapeutics Stock on Thursday? MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.
benzinga.com AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst AbbVie reports Phase 3 INTREPID trial results for lutikizumab in treating moderate to severe cases of hidradenitis suppurativa.- benzinga.com AbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1Lutikizumab met 8 ranked secondary…